Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-NDZhongguo shuxue zazhi

Efficacy of early plasma exchange in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease

  1. 1Department of Transfusion Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China
  2. 2First Clinical Medical College, Gannan Medical University, Ganzhou 341000, China
  3. 3Department of Critical Care Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China

Abstract

[Objective] To evaluate the efficacy and safety of adding early plasma exchange (PE) at the initiation of intensive immunosuppressive therapy in patients with anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis (DM) complicated by rapidly progressive interstitial lung disease (RP-ILD). [Methods] A retrospective analysis was conducted on patients diagnosed with anti-MDA5 antibody-positive DM with RP-ILD at our hospital from May 2021 to May 2024. Patients were grouped according to treatment regimen: the PE group (n=14) received PE (1.0-1.2 times the circulating plasma volume per session, three times per week) in addition to the intensive immunosuppressive regimen; the IS group (n=28) received the same intensive immunosuppressive regimen alone. Survival rates, symptom improvement, laboratory parameters, and adverse events were compared between the two groups. [Results] The 2-year cumulative survival rate in the PE group was 92.9% (13/14), significantly higher than that in the IS group (60.7%, 17/28) (P<0.05). In the PE group, respiratory symptoms improved markedly, and serum KL-6 and ferritin levels and anti-MDA5 antibody titers decreased significantly from baseline (all P<0.001), with greater reductions than those in the IS group. PE-related adverse events occurred in 3 patients (3/14, 21.4%), including one case each of allergic reaction, hypotension, and hypocalcemia; all resolved with symptomatic management. The incidence of severe infection was 21.4% (3/14) in the PE group and 25.0% (7/28) in the IS group, with no statistically significant difference (P=1.000). [Conclusion] For patients with anti-MDA5 antibody-positive DM-RP-ILD, early addition of PE to intensive immunosuppressive therapy can improve survival, ameliorate pulmonary lesions, and reduce serum biomarker levels without significantly increasing the risk of infection, demonstrating promising clinical application value.

Related

  1. Staged multi-target therapy for anti-MDA5-positive dermatomyositis-associated rapidly progressive interstitial lung disease: a case report.
    Lvdan Zhang, Mengwen Jiao, Yan Hou +5
    Respiratory medicine case reportsPeer-reviewedCC BY-NCFull textEpidemiology & public healthEurope PMC
  2. Rituximab Combined With Azathioprine for Relapsed Anti-MDA5 Antibody-Positive Dermatomyositis With Interstitial Lung Disease: A Case Report.
    Hiroki Ozaki, Yuki Inoue
    Case reports in rheumatologyPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  3. Candidate molecular endotypes and dynamic risk prediction in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a systematic scoping review
    Zhiwei Zuo, Jianguo Yang, Jianbin Li +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMC
  4. Rapidly Progressive Interstitial Lung Disease with Coexisting Anti-MDA5 and Anti-OJ Antibodies Successfully Treated with Intensive Immunosuppression and Plasma Exchange
    Daisuke Nakatani, Hideaki Yamakawa, Keiichi Akasaka +5
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedGeneral medicineJ-STAGE
  5. Fc N-glycosylation heterogeneity of anti-MDA5 IgG is associated with interstitial lung disease severity via regulating FcγR/C1q signaling in MDA5 + dermatomyositis: a cross‑sectional study.
    Jiangfeng Zhao, Zhihua Yin, Li Guo +6
    Arthritis research & therapyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
BibTeX
@article{yanhua2026efficacy,
  title = {{Efficacy of early plasma exchange in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease}},
  author = {WEN Yanhua and WEN Peishan and DING Shuchang and QIU Fang and XIE Jiangbo},
  journal = {Zhongguo shuxue zazhi},
  year = {2026},
  month = oct,
  doi = {10.13303/j.cjbt.issn.1004-549x.2026.10.014},
  url = {https://doi.org/10.13303/j.cjbt.issn.1004-549x.2026.10.014},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Efficacy of early plasma exchange in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease
AU  - WEN Yanhua
AU  - WEN Peishan
AU  - DING Shuchang
AU  - QIU Fang
AU  - XIE Jiangbo
PY  - 2026
DA  - 2026/10/01
JO  - Zhongguo shuxue zazhi
DO  - 10.13303/j.cjbt.issn.1004-549x.2026.10.014
UR  - https://doi.org/10.13303/j.cjbt.issn.1004-549x.2026.10.014
AB  - [Objective] To evaluate the efficacy and safety of adding early plasma exchange (PE) at the initiation of intensive immunosuppressive therapy in patients with anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis (DM) complicated by rapidly progressive interstitial lung disease (RP-ILD). [Methods] A retrospective analysis was conducted on patients diagnosed with anti-MDA5 antibody-positive DM with RP-ILD at our hospital from May 2021 to May 2024. Patients were grouped according to treatment regimen: the PE group (n=14) received PE (1.0-1.2 times the circulating plasma volume per session, three times per week) in addition to the intensive immunosuppressive regimen; the IS group (n=28) received the same intensive immunosuppressive regimen alone. Survival rates, symptom improvement, laboratory parameters, and adverse events were compared between the two groups. [Results] The 2-year cumulative survival rate in the PE group was 92.9% (13/14), significantly higher than that in the IS group (60.7%, 17/28) (P<0.05). In the PE group, respiratory symptoms improved markedly, and serum KL-6 and ferritin levels and anti-MDA5 antibody titers decreased significantly from baseline (all P<0.001), with greater reductions than those in the IS group. PE-related adverse events occurred in 3 patients (3/14, 21.4%), including one case each of allergic reaction, hypotension, and hypocalcemia; all resolved with symptomatic management. The incidence of severe infection was 21.4% (3/14) in the PE group and 25.0% (7/28) in the IS group, with no statistically significant difference (P=1.000). [Conclusion] For patients with anti-MDA5 antibody-positive DM-RP-ILD, early addition of PE to intensive immunosuppressive therapy can improve survival, ameliorate pulmonary lesions, and reduce serum biomarker levels without significantly increasing the risk of infection, demonstrating promising clinical application value.
SN  - 1004-549X
ER  -